טוען...
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects
Bruton´s tyrosine kinase (BTK) inhibitor (BTKi)s block the B-cell receptor (BCR) signaling cascade by binding to the BTK enzyme preventing the proliferation and survival of malignant and normal B cells. During the past decade, the clinical use of BTKis for the treatment of B-cell malignancies has ex...
שמור ב:
| הוצא לאור ב: | Front Immunol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8282344/ https://ncbi.nlm.nih.gov/pubmed/34276674 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.686768 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|